New “living drugs”—made from a patient’s own cells—can cure once incurable cancers. But can we afford them?

Quick Read

As someone who has lived with spinal muscular atrophy for all 30 years of my life, I was perplexed and disappointed that the recent approval of Novartis’ gene therapy Zolgensma was immediately overshadowed by outrage over the drug’s price: $2.125 million

Quick Read

Some biotech companies are offering a new way to soften the shock of drug prices: Insurers pay only if the patient improves

Quick Read

One of the namesakes of the federal “right-to-try” law confirmed Tuesday that he gained access to an experimental treatment thanks to the new law

Quick Read

Authors, including our Jeremy Sugarman, offer a call to action, ‘Companies that develop and distribute tools for genome editing have a responsibility to construct and implement policies and procedures to protect the integrity of science, to educate their employees to make certain that all research conducted within the company adheres to the highest ethical standards’

Quick Read

Who will pay for it? And how?

Quick Read

The approval of gene therapy for leukemia, expected in the next few months, will open the door to a radically new class of cancer treatments

Quick Read

The high-stakes fight over who invented a technology that could revolutionize medicine and agriculture heads to a courtroom Tuesday

Quick Read